Skip to main
SER
SER logo

SER Stock Forecast & Price Target

SER Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Serina Therapeutics is positioned favorably due to the advancement of its pipeline candidates, particularly with SER-252, which is targeting high-value indications in neurological diseases and pain management. The company's unique POZ Platform delivery technology offers significant advantages over traditional polymers, potentially enhancing the efficacy and market acceptance of its drug candidates. Importantly, the clinical success of SER-270 could further contribute to long-term growth and valuation, as current assessments do not factor in its potential, indicating significant upside potential for investors.

Bears say

Serina Therapeutics is facing significant financial challenges, highlighted by a reported net loss of $0.64 per share, which is considerably higher than previously estimated projections. The company is grappling with multiple risks, including delays in advancing its key drug candidate, SER-252, through clinical phases, regulatory approval hurdles, and heightened competition which could dampen market traction. Furthermore, the forecasted full-year net loss for 2025 has escalated to $2.01 per share, reflecting a substantial shift in outlook and indicating potential financial instability ahead.

SER has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Serina Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Serina Therapeutics, Inc. (SER) Forecast

Analysts have given SER a Strong Buy based on their latest research and market trends.

According to 2 analysts, SER has a Strong Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Serina Therapeutics, Inc. (SER)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.